anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Osteoarthritis is a chronic disease defined by progressive degradation of the joint as well as loss of cartilage on joint surfaces. The degeneration that occurs in the joint leads to changes in the catabolic and anabolic activity of chondrocytes. Osteoarthritis may induce pain, stiffness and limitation in range of motion of the joint and also may impact the quality of life. Platelet-rich plasma (PRP) is a fraction of plasma that contains platelets and multiple growth factors concentrated at high level. Because activated platelets have the potential to release growth factors, PRP has been clinically used to accelerate wound healing and tissue regeneration in orthopedic and oral surgery. Although several studies have assessed the effects of PRP on knee osteoarthritis, a higher level of evidence has not been provided. This study aimed to analyze the effect of PRP on knee osteoarthritis. After performing arthroscopic knee surgery plus intraoperative PRP in eligible patients, a second look arthroscopic surgery with intraoperative biopsy will be arranged 6 months later. Pre- and post-operative imaging and clinical outcomes will also be compared.
Patients receive olaparib PO BID on days 1-5 and 15-19 of each cycle and adavosertib PO QD on days 8-12 and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
Enrolled Subjects will have both a market-released transvenous pacing lead and investigational StealthTrac Temporary Pacing Lead placed and evaluated. Following StealthTrac Lead insertion, each subject will receive (1) one of three (3) study treatments intended to stabilize pacing capture thresholds and pacing impedance over time or receive no treatment. The three treatments are (1) Negative Pressure Wound Therapy, (2) Anti-Inflammatory Glucocorticoid and (3) increased electrode spacing achieved by the use of two inserted StealthTrac Leads. During the placement procedure, diagnostic echocardiograms will be performed to detect any new pericardial effusions. Once inserted, the StealthTrac Lead will be used to deliver high rate pacing (160 to 220 BPM) in clinically appropriate Subjects, to demonstrate suitability for use in transcatheter procedures that require brief periods of temporary pacing. Lead positions will be documented using fluoroscopic images before the Subject leaves the procedure room. On the following two days after the procedure, electrical performance will be evaluated in multiple postures and appropriate pacing and sensing will be confirmed during activity using ECG Holter monitor recordings. Subjects will also be asked patient-centric questions about their experience with the StealthTrac Lead throughout the study period. Evaluations will continue for a maximum of seven (7) days after the index procedure. Prior to StealthTrac Lead removal, an X-Ray will be taken to document the final lead position. A final follow-up will be performed 25-30 days after removal to identify any latent adverse events before the Subject exits the study.
PROBLEM TO BE SOLVED: To prepare a remarkable health food suitable for ensuring quiet sleep by using composite gealenicals as a main raw materials in order to suppress factors disturbing the sleep as much as possible. SOLUTION: This health food for quiet sleep contains the mixture of a Panax ginseng extract, a Ginkyo biloba extract, a Formes japonicus extract and calcium in a prescribed ratio as an active ingredient. For example, 1 pt.wt. of the Panax ginseng extract, 0.5-1.0 pt.wt. of the Ginkyo biloba extract, 0.1-0.5 pt.wt. of the Formes japonicus extract and 0.1-1.0 pt.wt. of the calcium are mixed.
The study does not investigate any health related interventions, neither a therapy nor medical device. The study aims to provoke peripheral nerve stimulation from time varying magnetic (so-called "gradient") fields in volunteers in order to measure gradient threshold levels in different configurations (different gradient coil units, different positions and postures). The experiments will provide new data regarding the interaction of gradient fields and function of the peripheral nervous system. These measurements are of general interest to quantify associated modeling uncertainties and validate current or future computational modeling techniques.

The experiments will use an MR scanner to generate the gradient fields used to induce stimulation. In normal mode the maximum gradient field allowed by the manufacturer may lead to peripheral nerve stimulation in approximately 50% of subjects. However, depending on the position and posture it may induce PNS in even fewer than 50% of subjects. Therefore, for the purpose of measuring stimulation thresholds it is necessary to operate the gradient units in experimental mode (with respect to the gradient field) as described in IEC 60601-2-33, i.e. the gradient limits set by the manufacturer will be disabled. As described in the standard, the gradient field will be increased slowly from non-stimulating levels until the volunteer perceives first stimulation sensations, at which point the gradient field will be stopped. This protocol does not lead to an increased risk of cardiac muscle stimulation compared to the normal mode, but only an increased likelihood of PNS with non-painful sensations in the skin, e.g. tingling, twitching or poking. PNS is not considered a health concern. The radio-frequency (RF) field will remain switched off, i.e. there is no risk of heating (the scanner will not acquire images in this mode).
Systems and methods for image annotation may be provided. Sample images and annotation information of each of the sample images may be obtained. Each of the sample images may include one or more annotations, and the annotation information of each of the sample images may relate to the one or more annotations included in the sample image. One or more candidate sample images may be selected from the sample images based on feature information of a target image to be annotated. Target annotation information of one or more target annotations to be added to the target image may be determined based on the annotation information of the one or more candidate sample images. The one or more target annotations may be added to the target image based on the target annotation information.
OBJECTIVE: Anticipatory nausea and vomiting are unpleasant symptoms observed before undergoing chemotherapy sessions. Less is known about the occurrence of symptoms since the advent of the new neurokinin-1 antagonist.
METHODS: This prospective cohort study was performed at a single Brazilian Institution. This study included breast cancer patients who received doxorubicin and cyclophosphamide chemotherapy and an appropriate antiemetic regimen (dexamethasone 10 mg, palonosetron 0.56 mg, and netupitant 300 mg in the D1 followed by dexamethasone 10 mg 12/12 h in D2 and D4). Patients used a diary to record nausea, vomiting, and use of rescue medication in the first two cycles of treatment. The prevalence of anticipatory nausea and vomiting was assessed before chemotherapy on day 1 of C2.
RESULTS: From August 4, 2020, to August 12, 2021, 60 patients were screened, and 52 patients were enrolled. The mean age was 50.8 (28-69) years, most had stage III (53.8%), and most received chemotherapy with curative intent (94%). During the first cycle, the frequency of overall nausea and vomiting was 67.31%, and that of severe nausea and vomiting (defined as grade>4 on a 10-point visual scale or use of rescue medication) was 55.77%. Ten patients had anticipatory nausea and vomiting (19.23%). The occurrence of nausea and vomiting during C1 was the only statistically significant predictor of anticipatory nausea and vomiting (OR=16, 95%CI 2.4-670.9, p=0.0003).
CONCLUSION: The prevalence of anticipatory nausea is still high in the era of neurokinin-1 antagonists, and failure of antiemetic control in C1 remains the main risk factor. All efforts should be made to control chemotherapy-induced nausea or nausea and vomiting on C1 to avoid anticipatory nausea.
Multiple myeloma (MM) is a plasma cell malignancy with progression marked by symptoms and signs of lowered resistance to infection, skeletal destruction, renal failure, and anemia. It is incurable and follows a relapsing course, with a median survival of approximately 4-5 years. The various therapies associated with disease control, are often associated with significant side effects, and ultimately, patients relapse. Therefore, assessment of health-related quality of life (HRQL) represents an important tool for evaluating the value of effective therapies when weighed against the potential toxic effects of treatment from the patient's perspective. Patients diagnosed with MM suffer from pain, fatigue, reduced physical and role functioning, and reduced overall HRQL compared with an age- and gender-matched population. These symptoms can improve with successful treatment with either cytotoxic therapy or supportive care. Many clinical studies for the treatment of multiple myeloma have been conducted in Korea, but none of them have evaluated the improvement in the quality of life in patients with multiple myeloma. Most study variables used to evaluate the quality of life of patients with multiple myeloma are subjective and limited. This study will observe the degree of the quality of life of patients in the early status of multiple myeloma before and after bortezomib administration by using EORTC-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions), validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma. Observational Study - No investigational drug administered.
The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.

Testosterone cypionate should not be used interchangeably with testosterone propionate because of differences in duration of action.

Testosterone cypionate is not for intravenous use.
Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation and damage to the liver cells. Typically, steatohepatitis involves inflammation of the liver related to fat accumulation, and mimics alcoholic hepatitis but is observed in patients who seldom or never consume alcohol. Nonalcoholic steatohepatitis can lead to serious liver damage, and ultimately cirrhosis. The present invention provides methods and compositions useful for the treatment or alleviation of nonalcoholic steatohepatitis and the pharmaceutical formulations for their administration to a human. Specifically, compositions comprised of lecithin, antioxidants and vitamin B complex are administered parenterally, most preferably by oral administration. Specific therapeutic formulations include admixtures of these compounds and specific dosage formulations include daily oral administrations of these compounds in tablet or powder forms.
PURPOSE: To prepare a controlled release pharmaceutical composition comprising an outer layer including a hydrophilic polymer and a filler and an inner layer including an active ingredient, having a controlled releasing rate of the inner layer by allowing the outer layer to be gradually removed by dissolution, etc., and useful for peptic esophagitis, etc. CONSTITUTION: The objective composition comprises (A) a pH-independent outer layer including a hydrophilic polymer such as a cellulose ether, and polyvinylpyrrolidone and one or more filler such as microcrystalline cellulose, and (B) one or more inner layers each containing an active ingredient such as an H2 -antagonist (e.g. ranitidine) or a serotonin antagonist (e.g. sumatriptan). The composition is constituted so that the outer layer may be gradually removed by a combination of dissolution and erosion and the one or more inner layer may be gradually removed by a combination of dissolution and erosion or rapidly disintegrated when once being exposed. The weight ratio of the inner layer to the outer layer is preferably (1/1) to (1/5).
Generalized convulsive status epilepticus (GCSE) is a common neurological emergency in children with significant morbidity and mortality. Benzodiazepines (Bzs) are the initial anti-seizure medications (ASMs) for children with GCSE, but nearly a third of cases are not controlled by (Bzs). Moreover, about 40% of cases not responding to BZs are not controlled by second-line ASMs.

Ketogenic diet (KD) has been classically used for treating children with drug resistant epilepsy. Recently, KD has been used for refractory and super refractory status epilepticus. However, KD takes time to achieve ketosis and may be practically challenging in emergency situations and critically ill patients. Exogenous ketone esters (EKE) could be a more convenient and rapid way to achieve ketosis in acute settings.
In a new process for removing inactive ballast proteins and ballast polypeptides from solutions of kallikrein-trypsin inhibitor (KTI) of different degrees of purity, the solutions are treated with non-specific proteases (which may be in immobilized form) which do not inhibit KTI, and the resulting peptides and amino acids are subsequently separated from the KTI by conventional physical methods. Highly concentrated infusion solutions of KTI are used in the treatment of pancratitis and states of shock. Such solutions should be as free as possible from inactive proteins. The process is technically simple to carry out, and gives purified KTI in quantitative yield. In an example, crude KTI (193.3 kallikrein inactivator unit/mg protein) was incubated at 40 degrees C with proteinase K immobilized on an oxirane-acrylamide gel. KTI with an activity of 201.3 kallikrein inactivator units/mg protein was obtained (enrichment factor 1.04), When starchimmobilized subtilisin was used as the protease and enrichment factor of 3.2 was obtd.
Subjects randomized to placebo HCQ. Subjects will receive 200 - 400 mg of HCQ placebo (1-2 pills), based upon IBW, taken daily for 12 months.
PURPOSE:To isolate a novel antibiotic substance from a culture and use the antibiotic substance as a remedy for mycosis, etc., by cultivating a microorganism, belonging to the genus Streptosporangium and capable of producing the titled novel antibiotic substance. CONSTITUTION:A strain, belonging to the genus Streptosporanium, e.g. Streptosporangium sp. SF-2381 (FERM-P No.8299), is cultivated in a culture medium containing glucose, dextrin, soybean flour, peptone, inorganic salt, etc., under aerobic conditions. Microbial cells are removed from the culture fluid, and the resultant product is adsorbed from the filtrate in an adsorbent and eluted with methanol to afford the aimed antibiotic substances SF-2381A and/or SF-2381B. The resultant substances exhibit the following properties respectively; Melting point; 151-153 deg.C and 150-153 deg.C. Soluble in water and methanol and insoluble in acetone and chloroform. White powder, etc. The substances have powerful antimicrobial activity against fungi.
BACKGROUND: Ictal stereo-encephalography (sEEG) biomarkers for seizure onset zone (SOZ) localization can be classified depending on whether they target abnormalities in signal power or functional connectivity between signals, and they may depend on the frequency band and time window at which they are estimated.
NEW METHOD: This work aimed to compare and optimize the performance of a power and a connectivity-based biomarker to identify SOZ contacts from ictal sEEG recordings. To do so, we used a previously introduced power-based measure, the normalized mean activation (nMA), which quantifies the ictal average power activation. Similarly, we defined the normalized mean strength (nMS), to quantify the ictal mean functional connectivity of every contact with the rest. The optimal frequency bands and time windows were selected based on optimizing AUC and F2-score.
RESULTS: The analysis was performed on a dataset of 67 seizures from 10 patients with pharmacoresistant temporal lobe epilepsy. Our results suggest that the power-based biomarker generally performs better for the detection of SOZ than the connectivity-based one. However, an equivalent performance level can be achieved when both biomarkers are independently optimized. Optimal performance was achieved in the beta and lower-gamma range for the power biomarker and in the lower- and higher-gamma range for connectivity, both using a 20 or 30 s period after seizure onset.
CONCLUSIONS: The results of this study highlight the importance of this optimization step over frequency and time windows when comparing different SOZ discrimination biomarkers. This information should be considered when training SOZ classifiers on retrospective patients' data for clinical applications.
OBJECTIVE: To assess early-onset sepsis as a risk factor of peri-intraventricular hemorrhage in premature infants born at less than or equal to 34 weeks' gestation and admitted to a neonatal intensive care unit (NICU).
METHODS: This retrospective cohort study included premature patients born at less than or equal to 34 weeks' gestation who were admitted to the NICU of a tertiary hospital in southern Brazil, and born from January 2017 to July 2021. Data were collected from patients' medical records. Early-onset sepsis was measured according to the presence or absence of diagnosis within the first 72 hours of life, whereas the outcome, peri-intraventricular hemorrhage, was described as the presence or absence of hemorrhage, regardless of its grade.
RESULTS: Hazard ratios were calculated using Cox regression models. A total of 487 patients were included in the study, of which 169 (34.7%) had some degree of peri-intraventricular hemorrhage. Early-onset sepsis was present in 41.6% of the cases of peri-intraventricular hemorrhage, which revealed a significant association between these variables, with increased risk of the outcome in the presence of sepsis. In the final multivariate model, the hazard ratio for early-onset sepsis was 1.52 (95% confidence interval 1.01-2.27).
CONCLUSION: Early-onset sepsis and the use of surfactants showed to increase the occurrence of the outcome in premature children born at less than or equal to 34 weeks' gestation. Meanwhile, factors such as antenatal corticosteroids and gestational age closer to 34 weeks' gestations were found to reduce the risk of peri-intraventricular hemorrhage.
Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
Patients will be treated with NBL-028 at starting dose of 0.01 mg/kg in dose escalation stage. In dose expansion stage, patients will be treated with NBL-028 at the recommended dose or multiple doses (if necessary) determined in the dose escalation stage.
Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
The number of participants in this group are anticipated to be 30. This group will be receiving only Kinesio Taping relaxation technique (muscle inhibition technique). In kinesio taping technique while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position on the upper trapezius muscle.
PURPOSE: To obtain the subject agent containing an extract of Trapa japonica Flerov., safe to the skin, having greatly high cell-activating effect, thus capable of maintaining fresh skin through its revitalization. CONSTITUTION: This cell activator contains an extract of Trapa japonica Flerov. The extraction is pref. accomplished by using ethanol, or its mixture with water. Specifically, for example, 300ml of a 50% aqueous ethanol solution is added to 10g of dry fruits of Trapa japonica Flerov. and the system is left to stand for 5 days while agitating it at times. The extract can be prepared into cosmetics of various formulations through incorporation of e.g. a liquid oil such as squalene, solid oil such as beeswax, activator, humectant such as glycerol., etc.
The JUMP method focuses more on the mental activity involved in constructing mathematical knowledge. There is a strong emphasis on symbolic math (numbers, letters, mathematical symbols). Manipulatives are used prescriptively, in lessons carefully scaffolded to help students connect the objects (e.g., three buttons) to what they are intended to stand for (the magnitude "3").
Metformin medication starts on 12-14 weeks of gestation. The starting dosage is 1 tablet (500 mg) x1 and it is increased gradually 1 tablet a week up to 2+2 tablets (2000mg) daily. Duration of the treatment is approximately until one week before delivery. Otherwise metformin treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
PURPOSE: A cosmetic composition containing Vitis Radix extract with an effect of improving anti-wrinkling or skin elasticity is provided to suppress elastase activity without side effects. CONSTITUTION: A cosmetic composition for improving anti-wrinkling or skin elasticity contains Vitis Radix extract as an active ingredient. The Vitis Radix is root of Vitis vinifera or Vitis amurensis or dried material thereof. The content of the Vitis Radix extract is 0.0001-10 weight%. The Vitis Radix extract is obtained by mixing dried Vitis Radix and 5-10 time volume of extract solvent and macerating for 5-7 days. The dried material of Vitis Radix extract is obtained by extracting in a container with cooling condenser for 1-5 hours, filtering, concentrating, freeze-drying or spray-drying. The extract solvent is water, ethanol, methanol, acetone, ethyl acetate or chloroform.
NEW MATERIAL:A monoclonal antibody capable of specifically recognizing fucosylceramides having the following properties. Ig class: IgM and derivation of the fucosylceramides: ceramide monoglycoside fraction of neutral glucolipid obtained by extraction from human cancer tissue and purification thereof. Capable of reacting with cell lines derived from lung cancer, stomach cancer, colon cancer and noma. Having no reactivity with cells of normal peripheral blood lymphocyte, normal erythrocyte, normal fibroblast, leukemia, cancer of the liver, mammary cancer, neutrablastoma, etc. USE:A diagnostic for human cancer. PREPARATION:A zooblast is immunized with a neutral glucolipid fraction obtained, e.g., by separation from human noma tissue and purification thereof and the resultant immunized zooblast is fused with a myeloma cell to form a hybridoma. The resultant hybridoma is subjected to cloning and a clone line capable of producing a monoclonal antibody specifically recognizing fucosylceramides is selected therefrom. The selected clone is cultured to obtain the objective monoclonal antibody.